1. Introduction
===============

The CCN family of proteins is an acronym for cysteine-rich protein 61 (CYR61), connective tissue growth factor (CTGF) and nephroblastoma overexpressed (NOV), which were first identified in mouse, human and chicken in the early 1990s ([@b1-ijmm-36-06-1451]--[@b3-ijmm-36-06-1451]). Another three family members exhibiting the same basic structure domains of the first three CCN members have since been identified. The latter three members are involved in the Wnt-1 inducible signalling pathway and consist of Wnt-1-induced secreted protein-1 (WISP-1), WISP-2, and WISP-3 ([@b4-ijmm-36-06-1451]). As each CCN family member has several names associated with its structures or functions, the official nomenclature has been recommended ([Table I](#tI-ijmm-36-06-1451){ref-type="table"}).

CCNs are present in vertebrates, including zebrafish, poultry such as chickens, rodents including mice and rats, as well as humans and have been conserved during evolution. CCNs, with the exception of CCN5, which lacks a cysteine knot domain (CT) module, comprise an N-terminal secretory signal peptide and four functional domains: an insulin-like growth factor-binding protein domain (IGFBP), a Von Willebrand factor domain (VWC), a thrombospondin type-1 repeat module (TSP-1), and a CT ([Fig. 1A](#f1-ijmm-36-06-1451){ref-type="fig"}). The two N-terminal domains are separated from the two C-domains by a variable linking sequence of amino acids ([@b5-ijmm-36-06-1451]). According to the domains CCNs, except CCN5, share five common exons, the first of which codes the signal sequence, while the other CCNs sequentially code the four functional domains with corresponding numbers of amino acids ranging from 349 to 381 ([@b6-ijmm-36-06-1451]).

The four discrete functional domains have different molecular structures that determine the types of binding partners and ligands with which they interact, resulting in a variety of biological functions. The known binding partners of each domain are different: insulin-like growth factors (IGFs) bind with IGFBP; transforming growth factor β (TGF-β), bone morphogenic proteins (BMPs) and integrins bind with VWC; vascular endothelial growth factor (VEGF), LDL receptor proteins (LRPs), heparan sulphate proteoglycans (HSPGs) and integrins bind with TSP-1; and VEGF, LRPs, integrins, neurogenic locus notch homolog protein 1 (Notch1), fibulin C1, HSPGs and integrins bind with CT ([@b7-ijmm-36-06-1451],[@b8-ijmm-36-06-1451]) ([Fig. 1B](#f1-ijmm-36-06-1451){ref-type="fig"}).

2. Expression profiles and subcellular localization
===================================================

CCNs exhibit different expression profiles and transcript levels in different tissues, organs and tumors ([Tables II](#tII-ijmm-36-06-1451){ref-type="table"} and [III](#tIII-ijmm-36-06-1451){ref-type="table"}). The different expression levels of CCNs observed in embryonic tissues compared with that of adult organs indicates a potential role in development ([Table IV](#tIV-ijmm-36-06-1451){ref-type="table"}). The changing transcript levels in tumors mean that CCNs may also be important during tumorigenesis.

The subcellular localization of each of the CCNs is also different. Immunohistochemical localization of CCN1 protein has indicated that invasive carcinoma cells show significant cytoplasmic and perinuclear protein overexpression compared to non-neoplastic ductal epithelium in invasive ductal carcinoma, whereas in ductal carcinoma *in situ* and lobular carcinoma *in situ*, CCN1 expression was weaker and heterogeneous ([@b9-ijmm-36-06-1451]). Previous findings have shown that CCN1 was detected, albeit not abundantly, in culture medium ([@b10-ijmm-36-06-1451]). CCN2 protein was detected in the nuclei of B16 (F10) cells and at the cell membrane, but was rarely detectable in the cytoplasm and the cell culture medium ([@b10-ijmm-36-06-1451],[@b11-ijmm-36-06-1451]). CCN3 was detected in the medium, extracellular matrix (ECM) and at the cell membrane ([@b12-ijmm-36-06-1451]--[@b14-ijmm-36-06-1451]). A previous study revealed strong immunohistochemical staining of CCN4, CCN5 and CCN6 in normal colorectal epithelial cells, which was confined primarily to the cell membrane with slight staining of stromal tissue. In colorectal cancer (CRC) tissues, cell membrane and cytoplasmic staining were assessed. Membrane staining showed a reduction in CCN4, CCN5 and CCN6, whereas cytoplasmic staining showed a reduction in CCN5 but an increase in CCN4 and CCN6 ([@b15-ijmm-36-06-1451]). Furthermore, CCN5 is mainly localized to the nucleus in rat and human tissues ([@b16-ijmm-36-06-1451]).

3. CCN receptors
================

Similar to some ECM proteins, CCNs mediate cell functions, embryonic development, angiogenesis, wound healing, fibrosis, inflammation, tumorigenesis and development primarily through binding and interacting with well-known receptors, including integrins, HSPGs, IGFs, and lipoprotein receptor-related proteins (LRPs). Signalling pathways, such as Wnts, TGF-β, insulin receptor signalling (IRS) and Notch, are involved in the regulation of these cell functions. The interaction of CCNs with receptors and other main cytokines has been briefly summarised ([Fig. 2](#f2-ijmm-36-06-1451){ref-type="fig"}).

Role of integrins in CCN functions
----------------------------------

Integrins, found as heterodimers consisting of α- and β-subunits are common transmembrane receptors that mediate cell-to-cell and cell-to-ECM adhesive interactions while also transducing signals from the ECM to the cell interior and vice versa. Currently, there are 24 members in the integrin family that have been identified to have 18 α-subunits and 8 β-subunits in their structures. In previous decades, it has been shown that integrins are associated with the different functions of CCNs ([@b8-ijmm-36-06-1451],[@b17-ijmm-36-06-1451]) ([Table V](#tV-ijmm-36-06-1451){ref-type="table"}).

HSPGs
-----

HSPGs are known to serve as co-receptors with integrins under certain circumstances ([@b18-ijmm-36-06-1451]). Heparin and HSPGs play important roles in modulating cell adhesion and fibrosis through TSP or CT domains ([@b19-ijmm-36-06-1451],[@b20-ijmm-36-06-1451]). CCNs are also capable of binding to HSPGs and mediate cell adhesion and Wnt signalling in some cell types ([@b21-ijmm-36-06-1451]--[@b23-ijmm-36-06-1451]). Furthermore, it has been previously demonstrated that CCN2 binds to fibronectin (HSPG2) through the CT domain and regulates cell functions ([@b24-ijmm-36-06-1451],[@b25-ijmm-36-06-1451]).

IGFs
----

The IGF family, which includes the polypeptide ligands IGF-I and IGF-II, two types of cell membrane receptors (IGF-IR and IGF-IIR), six binding proteins (IGFBP-1 to IGFBP-6) and IGFBP proteases play an important role in various types of cancer ([@b26-ijmm-36-06-1451]). The IGFs have interactions with various molecules that are known to be involved in cancer development and progression. CCNs may bind IGFs with low affinity ([@b27-ijmm-36-06-1451]), however, the impact on several cell functions needs to be examined. In previous decades, the regulative role of CCNs in co-ordinating cell functions has been a major research focus. Overexpression of CCN2 in chondrocytes elevates the mRNA transcript levels of IGF-I and IGF-II, resulting in increased bone growth ([@b28-ijmm-36-06-1451]). Conversely, CCN6 decreases the IGF-1-induced activation of the IGF-IR, and two of its main downstream signalling molecules, insulin receptor substrate 1 (IRS1) and extracellular signal-regulated kinase (ERK)-1/2 in inflammatory breast cancer cells ([@b29-ijmm-36-06-1451]). Downregulation of CCN6 enhances the effects of IGF-I and increases the growth, motility and invasiveness of human mammary epithelial cells ([@b30-ijmm-36-06-1451]).

Other receptors
---------------

CCNs have been reported to bind receptors, such as LRPs ([@b21-ijmm-36-06-1451]). CCN2 is known to regulate the cell adhesion and modulation of Wnt signalling in certain cell types by binding to LRP-1 and LRP-6 ([@b22-ijmm-36-06-1451],[@b23-ijmm-36-06-1451]). CCN2 binds bone morphogenetic protein-4 (BMP-4) and TGF-β1 through its VWC domain leading to the inhibition of BMP and TGF-β signalling ([@b31-ijmm-36-06-1451]). CCN2 binds VEGF through its TSP and CT domains and inhibits VEGF-induced angiogenesis ([@b32-ijmm-36-06-1451]). CCN3 binds to the epidermal growth factor (EGF)-like repeat region of Notch1 via its CT domain. The CCN3-Notch association exerts a positive effect on the Notch signalling pathway and suppresses the differentiation of certain myogenic cells ([@b33-ijmm-36-06-1451]). Other receptors include ECM protein (fibulin 1C), a calcium-binding protein (S100A4), ion channels (calcium voltage-independent and Cx43 gap junction) and a subunit of RNA polymerase II, which have also been reported to interact with CCNs ([@b34-ijmm-36-06-1451]--[@b36-ijmm-36-06-1451]).

4. Interactions with other cytokines
====================================

TNF-α
-----

TNF-α regulates CCN1 and CCN2 in a cell-type-specific manner. TNF-α represses CCN1 and CCN2 expression in chondrocytes but induces CCN1 expression in osteoblasts and CCN2 expression in synovial cells ([@b37-ijmm-36-06-1451]--[@b39-ijmm-36-06-1451]). Kular *et al* identified that TNF-α stimulated CCN3, CCN4 and CCN6 expression in melanocytes, cardiac myocytes and fibroblasts and fibroblast-like synoviocytes, respectively. By contrast, TNF-α stimulated CCN3 expression but exerted an inhibitory effect on CCN4 expression in cultured astrocytes ([@b40-ijmm-36-06-1451]).

TGF-β
-----

TGF-β has been reported to promote the expression of CCN1, CCN2, CCN4 and CCN5 but represses the expression of CCN3 in chondrosarcoma-derived HCS-2/8 and murine osteoblastic cells ([@b37-ijmm-36-06-1451],[@b41-ijmm-36-06-1451]). By contrast, the expression levels of CCN2, CCN3 and CCN4 were inversely correlated with TGF-β in leiomyomas ([@b42-ijmm-36-06-1451]). Thus, CCN2 is closely associated with TGF-β as this interaction represses the expression of TGF-β signalling inhibitors (such as Smad7) through the VWC domain ([@b43-ijmm-36-06-1451]).

5. Other signalling pathways
============================

CCNs have been shown to be associated with the Wnt signalling pathway ([@b4-ijmm-36-06-1451],[@b41-ijmm-36-06-1451]--[@b49-ijmm-36-06-1451]). Knockdown of CCN1 expression reduced the Wnt3A-induced oestrogenic differentiation demonstrating that CCN1 expression may be involved in the Wnt3A-induced osteoblast differentiation of mesenchymal stem cells ([@b44-ijmm-36-06-1451]). On the other hand, overexpression of CCN1 has also been shown to induce the expression of Wnt/β-catenin transcriptional targets and the formation of secondary body axes ([@b45-ijmm-36-06-1451]). Overexpression of CCN2 has been shown to induce the expression of Wnt/β-catenin transcriptional target genes of c-myc and cyclin D1 ([@b46-ijmm-36-06-1451]), whereas the overexpression of CCN2 decreased the effects of Wnt3 ([@b47-ijmm-36-06-1451]). Notably, CCN3 has been shown to inhibit Wnt/β-catenin signalling pathway through the suppression of BMP-2 activity ([@b48-ijmm-36-06-1451]). WISPs (CCN4, CCN5 and CCN6) have been associated with Wnt-1-induced transformation ([@b4-ijmm-36-06-1451],[@b49-ijmm-36-06-1451]).

CCN2 has been shown to induce chondrocyte differentiation, through a p38 mitogen-activated protein kinase (p38/MAPK), and proliferation, through the p44/42 MAPK/ERK ([@b49-ijmm-36-06-1451]).

6. CCNs in pathophysiological disorders
=======================================

CCNs and pathophysiological cell functions
------------------------------------------

The functions of CCNs have been revealed in a wide range of cell types, regulating their cell functions through a variety of mechanisms. CCN1 increased cell adhesion and migration through the integrin α6β1-HSPG co-receptors in fibroblasts, endothelial cells and vascular smooth muscle cells ([@b50-ijmm-36-06-1451],[@b51-ijmm-36-06-1451]). In endothelial cells, CCN1 has also been shown to promote cell adhesion, migration, survival, growth factor-induced mitogenesis and endothelial tubule formation via integrin α6β1 ([@b52-ijmm-36-06-1451]). CCN2 promoted the adhesion and migration of microvascular endothelial cells through an integrin-αvβ3-dependent mechanism ([@b53-ijmm-36-06-1451]). CCN3 increased the adhesion of normal melanocytes to collagen type IV ([@b54-ijmm-36-06-1451]). However, CCN3 expression was also decreased immediately after wounding or re-epithelialization ([@b55-ijmm-36-06-1451]), indicating the ability of CCN3 to negatively regulate fibroblast proliferation. CCN4 stimulated the migration and proliferation through integrin α5β1 in vascular smooth muscle cells ([@b56-ijmm-36-06-1451]). CCN4 has also been verified to promote the proliferation of hepatic stellate cells *in vitro* ([@b57-ijmm-36-06-1451]). CCN5 increased cell proliferation and survival against Streptozotocin in pancreatic cells ([@b58-ijmm-36-06-1451]). However, in vascular smooth muscle cells, CCN5 negatively regulated smooth muscle cell proliferation and motility ([@b59-ijmm-36-06-1451]). An inhibitory effect on *in vitro* growth of the human mammary epithelial cells function was also assigned to CCN6 ([@b60-ijmm-36-06-1451]).

CCNs in embryonic development and angiogenesis
----------------------------------------------

CCN expression profiles appear to be integral to the development of several key organ systems. CCN1 expression has been closely associated with the development of skeletal, cardiovascular, and neuronal systems during mice embryogenesis, best demonstrated by a CCN1 knockout mice model which exhibited aberrations in vascular development ([@b61-ijmm-36-06-1451],[@b62-ijmm-36-06-1451]). CCN2 knockout mice died at birth, due to respiratory failure resulting from hypoplastic lungs and poor thoracic development ([@b63-ijmm-36-06-1451]). A CCN2 knockdown zebrafish model showed bone defects and disruption in notochord development ([@b64-ijmm-36-06-1451]). CCN3 mutant mice exhibited skeletal and cardiac abnormalities, such as cardiomyopathy, muscle atrophy, and cataract formation ([@b65-ijmm-36-06-1451]). Evidence suggests that CCN4 has an an important regulatory function in skeletal growth and bone repair ([@b66-ijmm-36-06-1451]). The role of CCN5 remains unclear; however, it may serve a multifunctional purpose in developing mice and human embryos ([@b67-ijmm-36-06-1451]). CCN6 mutations in humans cause autosomal recessive skeletal disease progressive pseudorheumatoid dysplasia, a juvenile-onset joint degenerative disease ([@b68-ijmm-36-06-1451]). However, CCN6-null or CCN6-overexpression mice exhibited no observable phenotype ([@b69-ijmm-36-06-1451]). These findings from CCN knockout mice models together with their known expression profiles in the developmental stages ([Table IV](#tIV-ijmm-36-06-1451){ref-type="table"}) suggest that CCN1 and CCN2 play an essential role, while the other four members may play a regulatory role, in human embryonic development.

Wound healing
-------------

CCN1 and CCN2 are involved in tissue repair, as the increased expression of the two CCNs has been observed during cutaneous wound healing, liver regeneration, in the heart after myocardial infarction and after bone fracture ([@b70-ijmm-36-06-1451]--[@b74-ijmm-36-06-1451]). Xu *et al* showed that CCN2 acted as a downstream effector of TGF-β enhancing the production of scar tissue indicating that the suppression of CCN2 may prevent a progressive fibrotic response to TGF-β stimulation ([@b75-ijmm-36-06-1451]). Of note, CCN3 transcripts were decreased during the first three days after wound formation or re-epithelialization ([@b55-ijmm-36-06-1451]).

Fibrosis
--------

CCN2 mRNA expression has been observed in fibrotic lesions ([@b76-ijmm-36-06-1451]--[@b80-ijmm-36-06-1451]). However, this pattern has not been observed in early non-fibrotic or atrophic lesions. The serum level of CCN2 protein was significantly increased and correlated with skin sclerosis and lung fibrosis in patients. These results indicate that CCN2 co-operates with TGF-β to maintain and possibly even exacerbate fibrosis ([@b76-ijmm-36-06-1451]). Evidence has shown that either CCN2 mRNA or the application of exogenous CCN2 protein was required for the development of persistent fibrosis in a mouse fibrosis model ([@b77-ijmm-36-06-1451],[@b78-ijmm-36-06-1451]). Lipson *et al* reported that the inhibition of CCN2 was capable of preventing and reversing the process of fibrosis in liver and diabetic nephropathy models ([@b79-ijmm-36-06-1451]). CCN5 overexpression inhibited profibrotic phenotypes via the PI3K/Akt signalling pathway in lung fibroblasts and in mice ([@b80-ijmm-36-06-1451]).

Inflammation
------------

Bacteria, such as *Yersinia*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Enterococcus faecalis*, and *Staphylococcus aureus*, have been shown to induce CCN1 and CCN2 expression in epithelial cells, indicating that CCN1 and CCN2 overexpression may be useful in the adaptation of epithelial cells in stressful situations ([@b81-ijmm-36-06-1451]). HeLa cells infected by *Coxsackievirus B3* induced CCN1 activation via JNK to mediate cell death ([@b82-ijmm-36-06-1451]). Bacteria-derived lipid factors have also been shown to induce CCN1 and CCN2 during infections ([@b83-ijmm-36-06-1451],[@b84-ijmm-36-06-1451]).

7. CCNs in cancers
==================

CCNs, except CCN5, have four highly conservative functional domains, but play different roles in the same cancer type. Each CCN member may also play different roles in varying cancer types through different signalling pathways ([Fig. 2](#f2-ijmm-36-06-1451){ref-type="fig"} and [Table VI](#tVI-ijmm-36-06-1451){ref-type="table"}). Some CCN members have already been associated with cancer staging and prognosis as well as contributing to tumorigenesis or metastasis formation ([@b85-ijmm-36-06-1451]--[@b93-ijmm-36-06-1451]). Other CCN members have been considered as diagnostic or prognostic markers and therapeutic target genes in certain cancer types ([@b46-ijmm-36-06-1451],[@b103-ijmm-36-06-1451],[@b104-ijmm-36-06-1451],[@b119-ijmm-36-06-1451],[@b120-ijmm-36-06-1451]).

CCN1
----

CCN1 mRNA and protein levels are increased in ovarian cancer cells and may play an important role in ovarian carcinogenesis ([@b85-ijmm-36-06-1451]). CCN1 is upregulated in prostate cancer cell lines and tumor tissues and is associated with the status of the tumor-suppressor gene p53 ([@b86-ijmm-36-06-1451]). CCN1 has also been shown to enhance prostate cancer cell migration via alterations of function to integrins ([@b87-ijmm-36-06-1451]). An immunohistochemical analysis of 112 human glioma and normal brain specimens showed that the levels of tumor-associated CCN1 protein were increased with tumor grade (P\<0.001), and this trend was verified with similar results identified in glioma cells ([@b88-ijmm-36-06-1451]). These results have identified a CCN1-dependent pathway that mediates cell growth, cell migration, and long-lasting signalling events in glioma cell lines and possibly astroglial malignancies. CCN1 is overexpressed in U343 glioma cells and has been linked with the integrin-linked kinase-mediated Akt and β-catenin-TCF/Lef signalling pathways ([@b89-ijmm-36-06-1451]). CCN1 is a transcriptional target of Hh-GLI signalling leading to increased vascularity and spontaneous metastasis of breast cancer cells ([@b90-ijmm-36-06-1451]). Zuo *et al* demonstrated that the overexpression of CCN1 in breast cancer is associated with the tumorigenesis, migration and invasion of cancer cells ([@b6-ijmm-36-06-1451]). CCN1 was expressed in \~30% of invasive breast cancer biopsies and played a role in breast cancer progression, possibly through its interactions with the avb3 receptor ([@b91-ijmm-36-06-1451]). CCN1 was found to be overexpressed in patients with endometrial carcinoma and indicative of a poor prognosis ([@b92-ijmm-36-06-1451]). CCN1 has also been shown to be overexpressed and correlate with invasion and metastasis in CRC ([@b93-ijmm-36-06-1451]).

Other studies, however, have shown different results. For instance, CCN1 expression was found to be reduced in endometrial cancer and lung cancer tissues compared to their paired normal tissues ([@b94-ijmm-36-06-1451],[@b95-ijmm-36-06-1451]). Notably, the expression levels of CCN1 were reduced in high-grade chondrosarcomas and advanced gastric cancers ([@b96-ijmm-36-06-1451],[@b97-ijmm-36-06-1451]).

CCN2
----

CCN2 mRNA and protein levels are increased in murine and human rhabdomyosarcoma cells ([@b98-ijmm-36-06-1451]). Overexpression of CCN2 increases breast cancer cell migration in Boyden chamber assays and promotes angiogenesis in chorioallantoic membrane assays compared to control cells *in vitro* ([@b99-ijmm-36-06-1451]). By contrast, a reduced expression of CCN2 in clinical breast cancer samples based on a qPCR study is associated with poor prognosis (P=0.021), metastasis (P=0.012), local recurrence (P=0.0024) and mortality (P=0.0072) ([@b100-ijmm-36-06-1451]). Similarly, findings in CRC are controversial. CCN2 may play an oncogenic role in the progression of well-differentiated CRC ([@b101-ijmm-36-06-1451]). However, Lin *et al* showed that lower CCN2 expression levels in CRC patients were associated with a higher peritoneal recurrence rate. Additionally, CCN2 overexpression decreased the incidence of peritoneal carcinomatosis and increased the rate of mice survival, but significantly decreased CRC cell adhesion ability *in vitro* ([@b102-ijmm-36-06-1451]). CCN2 overexpression was also found to be associated with poor prognosis in oesophageal squamous cell carcinoma, pancreatic cancer, high-grade chondro sarcomas and enchondromas ([@b46-ijmm-36-06-1451],[@b100-ijmm-36-06-1451],[@b103-ijmm-36-06-1451],[@b104-ijmm-36-06-1451]).

However, evidence suggests opposing roles for CCN2 ([@b102-ijmm-36-06-1451],[@b105-ijmm-36-06-1451]--[@b109-ijmm-36-06-1451]). In these studies, CCN2 acted as an inhibitor, tumor suppressor or a positive prognostic indicator. CCN2 overexpression plays an important inhibitory role on cell proliferation in non-small cell lung cancer cell lines ([@b105-ijmm-36-06-1451]). By contrast, in ovarian tumorigenesis, inactivation of the *CCN2* gene may play a role in disease progression ([@b106-ijmm-36-06-1451]). CCN2 expression is decreased in Wilms\' tumors and a high CCN2 expression exhibits improved prognostic features in intrahepatic cholangiocarcinoma and CRC patients ([@b102-ijmm-36-06-1451],[@b107-ijmm-36-06-1451]--[@b109-ijmm-36-06-1451]).

CCN3
----

In human prostate cancer, Maillard *et al* revealed that CCN3 overexpression in cancer cell lines compared with their epithelial localizations was consistent with a role for CCN3 in prostatic tumorigenesis ([@b110-ijmm-36-06-1451]). Manara *et al* found the primary musculoskeletal tumors that developed lung and/or bone metachronous metastases also exhibited CCN3 overexpression ([@b111-ijmm-36-06-1451]). A similar effect was observed for CCN3 in bone malignancies and cervical cancer, suggesting it acts as a promoter of tumor growth and thus a poor prognostic indicator ([@b112-ijmm-36-06-1451],[@b113-ijmm-36-06-1451]). The involvement of CCN3 in cervical cancer has been confirmed by a subsequent study ([@b114-ijmm-36-06-1451]). CCN3 transcripts and protein levels were increased in cervical cancer tissues when compared with the corresponding normal tissues. Overexpression of CCN3 was significantly associated with the stage of the disease (P=0.017) and with lymph node involvement (P=0.006). These results suggest that the overexpression of CCN3 is associated with a poorer prognosis in cervical cancer ([@b114-ijmm-36-06-1451]).

Other cancer types have resulted in inconsistent results compared to those mentioned above. CCN3-transfected glioma cells induced tumors to a lesser degree than their parental counterparts, which did not express detectable amounts of CCN3 ([@b115-ijmm-36-06-1451]). *In vitro*, CCN3 exerted an anti-proliferative effect and interfered with the S/G2 transition of the cell cycle, thereby inducing an artificial accumulation of glioblastoma cells (G59) at the S phase ([@b116-ijmm-36-06-1451]). CCN3 restored cell growth regulatory properties that were absent in chronic myeloid leukaemia and sensitized chronic myeloid leukaemia cells to imatinib-induced apoptosis ([@b117-ijmm-36-06-1451]). CCN3 protein levels were significantly modified in malignant adrenocortical tumors, but not in benign adrenocortical tumors ([@b118-ijmm-36-06-1451]). CCN3 suppressed the cell proliferation via interaction with the gap junction protein Connexin43 in glioma cells, and high levels of CCN3 reduced tumorigenicity, resulting in a lower rate of metastasis ([@b119-ijmm-36-06-1451],[@b120-ijmm-36-06-1451]). CCN3 *in vitro* has been reported to decrease the transcription and activation of matrix metal-loproteinases and suppress the invasion of melanoma cells, indicating that the downregulation of CCN3 expression is a potential mechanism for melanoma progression ([@b121-ijmm-36-06-1451]).

CCN4
----

CCN4 is downstream of Wnt-1 signalling and CCN4 overexpression in colon cancer and may play a role in colon tumorigenesis ([@b4-ijmm-36-06-1451]). It has been revealed that CCN4 transcripts are expressed at higher levels in tumor samples compared to normal tissue, and are higher in patients with Dukes\' stage B and C compared to Dukes\' A. Thus, CCN4 appears to act as a factor for stimulating aggressiveness in colon cancer ([@b15-ijmm-36-06-1451]). A similar behavior pattern was observed in oral squamous cell carcinoma cells as CCN4 enhanced their expression by increasing ICAM-1 expression through the αvβ3 integrin receptor and the ASK1, JNK/p38 and AP-1 signal transduction pathways ([@b122-ijmm-36-06-1451]).

By contrast, CCN4 inhibited the growth and metastasis of melanoma cells and its expression is increased in low metastatic cells compared to high metastatic cells ([@b123-ijmm-36-06-1451],[@b124-ijmm-36-06-1451]). CCN4 overexpression inhibits the motility and invasion of lung cancer cells through the inhibition of Rac activation *in vitro* ([@b125-ijmm-36-06-1451]). Similar results have been identified in clinical specimens in which CCN4 has been shown to be reduced in chondrosarcoma and breast cancer with poor prognosis, suggesting it is a putative tumor suppressor ([@b126-ijmm-36-06-1451],[@b127-ijmm-36-06-1451]).

CCN5
----

CCN5 has been shown to be increased in hepatocellular carcinoma compared to paired normal tissues ([@b128-ijmm-36-06-1451]), as well as in adrenocorticotropic hormone-secreting pituitary tumors compared to normal pituitaries ([@b129-ijmm-36-06-1451]). However, previous findings focusing on the role of CCN5 in breast cancer remain controversial. Ji *et al* reported that CCN5 mRNA and protein levels were increased in some breast cancer cells and in breast tumors from patients with poor prognosis ([@b130-ijmm-36-06-1451]). However, CCN5 mRNA and protein levels were significantly reduced as the cancer progressed from a non-invasive to invasive type in breast cancer, and CCN5 mRNA and protein levels were almost undetectable in poorly differentiated cancers compared to the moderately or well-differentiated samples ([@b131-ijmm-36-06-1451]). *In vitro* studies have shown that CCN5 was a negative regulator of growth, migration and invasion of breast cancer cells ([@b132-ijmm-36-06-1451],[@b133-ijmm-36-06-1451]).

CCN5 exhibits differing effects in other cancer types. For example, Yang *et al* examined CCN5 protein expression in 46 squamous cell/adenosquamous carcinoma samples and 80 adenocarcinoma samples using immunohistochemistry. The results of that study showed that the loss of CCN5 expression was associated with the metastasis, invasion and poor prognosis of gallbladder cancer ([@b134-ijmm-36-06-1451]). CCN5 mRNA and protein expression levels have been shown to be reduced in pancreatic adenocarcinoma, salivary gland tumors and CRC compared with the respective paired normal tissues ([@b4-ijmm-36-06-1451],[@b15-ijmm-36-06-1451],[@b135-ijmm-36-06-1451],[@b136-ijmm-36-06-1451]).

CCN6
----

CCN6 was overexpressed in 63% of the colon tumors analyzed and may be downstream of Wnt-1 signalling, thus playing a role in colon tumorigenesis ([@b4-ijmm-36-06-1451]). A similar result was obtained in a microsatellite instability subtype of CRC ([@b4-ijmm-36-06-1451],[@b137-ijmm-36-06-1451]). However, previous findings revealed that there is no significant difference in CCN6 mRNA levels expressed in the majority of CRC in comparison with paired normal tissues ([@b15-ijmm-36-06-1451]). CCN6 transcripts may also play a positive role in the development of hepatocellular carcinoma ([@b138-ijmm-36-06-1451]). Knockdown of CCN6 expression suppressed gastric cancer cell proliferation and migration via the Wnt/β-catenin signalling pathway *in vitro*, while a high expression of CCN6 indicated poor prognosis in a gastric cancer clinical cohort ([@b139-ijmm-36-06-1451]).

CCN6 mRNA was reduced in 80% of poor outcome cases of breast cancer, and was found to be essential to induce the process of epithelial-mesenchymal transition (EMT) in breast cancer ([@b60-ijmm-36-06-1451]). CCN6 overexpression inhibited cell growth and invasiveness in breast cancer cell lines ([@b140-ijmm-36-06-1451]) and CCN6 expression was reduced in breast cancer samples compared to paired normal tissues ([@b141-ijmm-36-06-1451]). Taken together, the evidence suggests CCN6 is a putative tumor suppressor in breast cancer.

8. Conclusion and perspectives
==============================

The perturbed expression of CCNs has been observed in a variety of malignancies. The aberrant expression of certain CCNs is associated with disease progression and poor prognosis. Different CCNs may play contrasting roles in the same cancer, while the same CCN may play different roles in various types of cancer. Further investigations may highlight their clinical relevance and application for predicting prognosis. CCNs comprise four functional domains and exhibit differential expression and functions in different cells and tissues albeit CCN5 lacks a CT module. CCNs can regulate cell functions by acting as ligands for integrins, heparin, and HSPGs, which are regulated by certain growth factors and cytokines, including IGFs, TGF-α and TGF-β, to fulfil their role in the consequent physiological and pathological events. Additionally, CCNs interact with a variety of receptors and cytokines by modulating downstream signal transduction. Insight into the detailed mechanisms involved in CCN-mediated regulation may be useful in understanding their roles and functions in tumorigenesis and cancer metastasis. This may provide new avenues for target therapy in certain malignancies.
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ADAM

:   a disintegrin and metalloprotease

BSP

:   bone sialic protein

COMP

:   cartilage oligomeric matrix protein

L1

:   CD171

LAP-TGF-β

:   TGF-β latency-associated peptide

iC3b

:   inactivated complement component 3

PECAM-1

:   platelet and endothelial cell adhesion molecule 1

uPA

:   urokinase-type plasminogen activator

uPAR

:   urokinase-type plasminogen activator receptor

VEGF

:   vascular endothelial growth factor

![(A) Structure of CCN proteins. The locations of the four structural domains (IGFBP, VWC, TSP-1 and CT) are compared. The two N-terminal domains are separated from the two C-domains (except CCN5) by hinge regions, susceptible to protease cleavage. The arabic numerals display the size of each domain and their relative positions. (B) Four domains of CCNs and the known binding partners. Integrins can bind with VWC, TSP-1 and CT domain, while VEGF, LRPs and HSPGs can bind with TSP-1 and CT domain. IGFBP, insulin-like growth factor-binding protein; VWC, Von Willebrand factor; TSP-1, thrombospondin type-1; CT, cysteine knot; VEGF, vascular endothelial growth factor; LRPs, lipoprotein receptor-related proteins; HSPGs, heparan sulphate proteoglycans.](IJMM-36-06-1451-g00){#f1-ijmm-36-06-1451}

![CCN protein interactions with receptors and other main cytokines. Top panels: TNF-α, TGF-β and Wnts and their downstream molecules interact with CCNs; Wnts: Wnt signalling pathway molecules; middle panel: CCNs and their well-known receptors; bottom panel: CCNs regulate cell functions, embryonic development, angiogenesis, wound healing, fibrosis, inflammation, tumorigenesis and development via different receptors and signaling pathways.](IJMM-36-06-1451-g01){#f2-ijmm-36-06-1451}

###### 

Nomenclature of the CCN family of proteins.

  Official name   Alternative names
  --------------- ----------------------------------------------------
  CCN1            CYR61, CTGF-2, IGFBP10, IGFBP-rP4, CEF10
  CCN2            CTGF, IGFBP8, IGFBP-rP2, HBGF-0.8, HCS24, ecogenin
  CCN3            NOV, NOVH, IGFBP9, IGFBP-rP3
  CCN4            WISP-1, Elm-1, IGFBP-rP8
  CCN5            WISP-2, CTGF-L, CTGF-3, HICP, Cop-1, IGFBP-rP7
  CCN6            WISP-3, IGFBP-rP9

CYR61, cysteine-rich protein 61; IGFBP, IGFBP-related protein; HBGF, heparin-binding growth factor; Hcs, human chondrosarcoma; Elm-1, expressed in low metastatic cells; HICP, haparin-induced CCN-like protein; Cop-1, card-only protein 1; WISP-1, Wnt-1 induced secreted protein-1.

###### 

Expression profiles of CCN family members: Breakdown by body sites.

  Breakdown by body sites   CCN1 (TPM)   CCN2 (TPM)   CCN3 (TPM)   CCN4 (TPM)   CCN5 (TPM)   CCN6 (TPM)
  ------------------------- ------------ ------------ ------------ ------------ ------------ ------------
  Adipose tissue            1243         621          0            77           0            0
  Adrenal gland             212          30           1548         30           0            0
  Ascites                   75           75           0            0            0            0
  Bladder                   33           66           0            0            0            0
  Blood                     0            8            8            0            0            0
  Bone                      474          1396         69           41           0            0
  Bone marrow               61           964          0            0            0            0
  Brain                     104          106          64           0            2            3
  Cervix                    123          20           144          0            0            20
  Connective tissue         462          1730         33           53           20           0
  Ear                       310          1677         931          62           0            0
  Embryonic tissue          98           244          0            28           0            9
  Eye                       100          277          4            33           0            0
  Heart                     122          22           11           0            0            33
  Intestine                 120          250          4            12           4            0
  Kidney                    208          521          23           4            9            4
  Larynx                    170          213          0            0            0            0
  Liver                     238          107          24           4            0            0
  Lung                      131          191          8            5            17           0
  Lymph                     0            0            0            0            0            0
  Lymph node                44           33           0            0            0            11
  Mammary gland             85           66           13           6            0            6
  Mouth                     45           513          30           0            0            0
  Muscle                    37           28           18           28           0            0
  Nerve                     1223         450          64           0            0            0
  Oesophagus                198          49           0            0            0            0
  Ovary                     167          177          19           9            0            0
  Pancreas                  168          281          9            14           0            0
  Parathyroid               0            0            0            0            0            48
  Pharynx                   24           24           0            0            0            0
  Pituitary gland           0            0            60           0            0            0
  Placenta                  215          77           0            0            250          0
  Prostate                  73           121          10           0            10           0
  Salivary gland            0            0            0            0            98           0
  Skin                      227          389          33           0            0            4
  Spleen                    393          711          0            37           18           0
  Stomach                   282          553          62           0            0            73
  Testis                    43           96           2            0            6            6
  Thymus                    75           100          0            0            0            0
  Thyroid                   364          472          21           0            0            0
  Tonsil                    0            0            0            0            0            0
  Trachea                   308          849          19           0            0            0
  Umbilical cord            581          1089         0            0            0            0
  Uterus                    348          400          21           51           12           0
  Vascular                  1219         3814         309          0            0            0

TPM, transcripts per million.

###### 

Expression profiles of CCN family members: Breakdown by health state.

  Breakdown by pathophysiology      CCN1 (TPM)   CCN2 (TPM)   CCN3 (TPM)   CCN4 (TPM)   CCN5 (TPM)   CCN6 (TPM)
  --------------------------------- ------------ ------------ ------------ ------------ ------------ ------------
  Adrenal tumor                     158          0            948          0            0            0
  Bladder carcinoma                 113          284          0            0            0            0
  Breast (mammary gland) tumor      53           42           0            10           0            10
  Cervical tumor                    57           0            57           0            0            28
  Chondrosarcoma                    676          1424         108          72           12           0
  Colorectal tumor                  79           35           0            0            8            0
  Oesophageal tumor                 231          57           0            0            0            0
  Gastrointestinal tumor            278          641          50           0            0            59
  Germ cell tumor                   87           501          11           18           0            15
  Glioma                            55           121          37           0            0            0
  Head and neck tumor               141          186          14           0            14           0
  Kidney tumor                      101          188          29           14           29           0
  Leukemia                          0            31           10           0            0            21
  Liver tumor                       229          156          52           0            0            0
  Lung tumor                        58           9            0            0            0            0
  Lymphoma                          27           0            0            0            0            0
  Non-neoplasia                     341          1407         0            10           0            0
  Normal                            187          319          45           10           32           3
  Ovarian tumor                     183          249          39           13           0            0
  Pancreatic tumor                  171          419          9            28           0            0
  Primitive neuroectodermal tumor   23           0            0            0            0            0
  Prostate cancer                   48           19           9            0            0            0
  Retinoblastoma                    0            0            0            0            0            0
  Skin tumor                        31           71           31           0            0            7
  Soft tissue/muscle tissue tumor   526          47           0            0            0            0
  Uterine tumor                     321          355          44           11           22           0

TPM, transcripts per million.

###### 

Expression profiles of CCN family members: Breakdown by developmental stage.

  Breakdown by developmental stage   CCN1 (TPM)   CCN2 (TPM)   CCN3 (TPM)   CCN4 (TPM)   CCN5 (TPM)   CCN6 (TPM)
  ---------------------------------- ------------ ------------ ------------ ------------ ------------ ------------
  Embryoid body                      214          457          0            57           0            0
  Blastocyst                         32           48           0            0            0            16
  Fetus                              53           132          52           25           39           7
  Neonate                            386          514          32           0            0            0
  Infant                             0            85           0            0            0            0
  Juvenile                           377          197          17           0            0            0
  Adult                              201          289          26           14           40           2

TPM, transcripts per million.

###### 

Integrins are associated with the functions of CCN proteins.

  Integrins   Involved CCN members     Cell functions affected                               Other ligands
  ----------- ------------------------ ----------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  α2β1        CCN1                     Migration, invasion, motility, lymphangiogenesis      Laminin, collagen, thrombospondin, E-cadherin, tenascin
  α5β1        CCN2, CCN3               Adhesion, growth, survival, angiogenesis              Fibronectin, osteopontin, fibrillin, thrombospondin, ADAM, COMP, L1
  α6β1        CCN1, CCN2, CCN3         Adhesion, growth                                      Laminin, thrombospondin, ADAM
  αDβ2        CCN1                     Adhesion                                              ICAM, VCAM-1, fibrinogen, fibronectin, vitronectin, plasminogen
  αMβ2        CCN1, CCN2               Adhesion                                              ICAM, iC3b, factor X, fibrinogen, ICAM-4, heparin
  αvβ3        CCN1, CCN2, CCN3         Angiogenesis, adhesion, migration, survival, growth   Fibrinogen, vitronectin, thrombospondin, fibrillin, tenascin, PECAM-1, fibronectin, osteopontin, BSP, MFG-E8, ADAM-15, COMP, ICAM-4, MMP, FGF-2, uPA, uPAR, L1, angiostatin, plasmin, cardiotoxin, LAP-TGF-β, Del-1
  αvβ5        CCN1, CCN2, CCN3, CCN4   Growth, survival, angiogenesis                        Osteopontin, BSP, vitronectin, LAP-TGF-β
  αIIbβ3      CCN1, CCN2               Hemostasis, thrombosis                                Fibrinogen, thrombospondin, fibronectin, vitronectin, ICAM-4, L1, CD40 ligand

ADAM, a disintegrin and metalloprotease; BSP, bone sialic protein; COMP, cartilage oligomeric matrix protein; L1, CD171; LAP-TGF-β, TGF-β latencyassociated peptide; iC3b, inactivated complement component 3; PECAM-1, platelet and endothelial cell adhesion molecule 1; uPA, urokinase-type plasminogen activator; uPAR, urokinase-type plasminogen activator receptor; VEGF, vascular endothelial growth factor.

###### 

Regulations of CCN members in various types of cancer: Clinical specimens and/or cancer cells *in vitro*.

  Tumor type (arranged A-Z)         CCN1   CCN2   CCN3   CCN4   CCN5   CCN6
  --------------------------------- ------ ------ ------ ------ ------ ------
  Breast cancer                     ↑      ↑             ↓      ↑/↓    ↓
  Cervical cancer                                 ↑                    
  Chondrosarcomas                   ↓      ↑      ↑      ↓             
  Chronic myeloid leukaemia                       ↓                    
  CRC                               ↑      ↑/↓           ↑      ↓      ↑
  Enchondromas                             ↑                           
  Endometrial cancer                ↑/↓                                
  Esophageal cancer                        ↑                           
  Gallbladder cancer                                            ↓      
  Gastric cancers                   ↓                                  ↑
  Glioma                            ↑             ↓                    
  Liver cancer                             ↓                    ↑      ↑
  Lung cancer                       ↓      ↓             ↓             
  Malignant adrenocortical tumors                 ↓                    
  Melanoma                                        ↓      ↓             
  Oral carcinoma                                         ↑             
  Ovarian cancer                    ↑      ↓                           
  Pancreatic cancer                        ↑                    ↓      
  Pituitary tumors                                              ↑      
  Prostate cancer                   ↑             ↑                    
  Salivary gland tumors                                         ↓      
  Rhabdomyosarcoma                         ↑                           
  Wilms\' tumor                            ↓      ↑                    

↑, positive correlation or upregulation; ↓, negative correlation or downregulation; ↑/↓, controversial regulations; CRC, colorectal cancer.
